Crizotinib

0:04:10

Crizotinib Resistance in ALK+ NSCLC

0:07:07

ROS1 Treatment Options: Crizotinib and Entrectinib - 2022 Program: Targeted Therapies Forum

0:04:58

How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?

0:00:56

Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements

0:02:52

Q&A: Cabozantinib for ROS1 after Progression on Crizotinib - Targeted Therapies in Lung Cancer 2023

0:05:28

CROWN study: lorlatinib vs crizotinib in 1L NSCLC

0:02:45

Crizotinib treatment in lung adenocarcinoma patient with ROS1 fusion – Video abstract ID 136297

0:01:06

METROS: crizotinib in ROS1+NSCLC long-term OS analysis in patients with brain metastasis

0:01:11

Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC

0:01:27

Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLC

0:03:24

Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLC

0:01:17

Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer

0:07:21

Ceritinib in Crizotinib-Resistant NSCLC

0:03:43

Lorlatinib takes CROWN in head-to-head comparison with crizotinib | Benjamin Solomon

0:03:56

Tumore del polmone: crizotinib adesso anche in prima linea per i pazienti ALK-positivi

0:02:09

ALTA-1L: brigatinib vs crizotinib in ALK+ aNSCLC

0:01:09

Darovasertib and crizotinib in uveal melanoma

0:02:03

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

0:04:00

ALTA-1L: final overall survival results of brigatinib vs crizotinib for ALK+ lung cancer

0:01:39

GRACE Targeted Therapies Lung Cancer 2021 - Treatment After Crizotinib In ROS1 Lung Cancer

0:07:02

Crizotinib for ALK-Rearranged NSCLC

0:13:28

DEBATE: ALK positive NSCLC - Front line therapy - Crizotinib

0:02:15

New ALK Inhibitor Drugs vs Xalkori (Crizotinib) for ALK+ Lung Cancer Patients

0:01:14

Dr. Rotow on First-Line Brigatinib Versus Crizotinib in ALK+ NSCLC